MannKind Corp (MNKD)

1.03
0.04 4.20
NASDAQ : Health Care
Prev Close 0.99
Open 0.98
Day Low/High 0.98 / 1.00
52 Wk Low/High 0.64 / 5.37
Volume 1.23M
Avg Volume 4.58M
Exchange NASDAQ
Shares Outstanding 429.16M
Market Cap 424.87M
EPS -0.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Here's Why MannKind (MNKD) Stock Is Down Today

Here's Why MannKind (MNKD) Stock Is Down Today

MannKind (MNKD) stock is plummeting in late-morning trading on Tuesday after reporting 2016 first quarter results.

MannKind Corporation Reports 2016 First Quarter Financial Results

MannKind Corporation Reports 2016 First Quarter Financial Results

Conference Call to Begin Today at 5:00 PM ET

MannKind and Its CEO Fail Simple Financial Literacy Test

MannKind and Its CEO Fail Simple Financial Literacy Test

MannKind is drowning in debt and fixed purchasing contracts but the company generates no revenue.

First Week of June 17th Options Trading For MannKind (MNKD)

First Week of June 17th Options Trading For MannKind (MNKD)

Investors in MannKind Corp saw new options begin trading this week, for the June 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MNKD options chain for the new June 17th contracts and identified one put and one call contract of particular interest.

Notable Thursday Option Activity: MNKD, ONVO, IRBT

Notable Thursday Option Activity: MNKD, ONVO, IRBT

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in MannKind Corp , where a total of 45,300 contracts have traded so far, representing approximately 4.5 million underlying shares. That amounts to about 46.9% of MNKD's average daily trading volume over the past month of 9.7 million shares.

MannKind To Discuss U.S. Commercialization Update For Afrezza®

MannKind To Discuss U.S. Commercialization Update For Afrezza®

- Analyst Call Scheduled for April 19, 2016 at 5:00 PM EDT -

MannKind Regains Afrezza® Marketing Rights

MannKind Regains Afrezza® Marketing Rights

Transition Ensures Innovative Inhalable Insulin Will Continue to be Available to Adults with Diabetes

Commit To Buy MannKind Corp At $1, Earn 50.4% Annualized Using Options

Commit To Buy MannKind Corp At $1, Earn 50.4% Annualized Using Options

Investors eyeing a purchase of MannKind Corp stock, but tentative about paying the going market price of $2.15/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2017 put at the $1 strike, which has a bid at the time of this writing of 42 cents.

MannKind (MNKD) Stock Drops on Q4 Loss

MannKind (MNKD) Stock Drops on Q4 Loss

MannKind (MNKD) stock is sinking in mid-morning trading on Tuesday after the biopharmaceutical company reported a wider-than-expected loss during the 2015 fourth quarter.

MannKind (MNKD) Stock Down in After-Hours Trading on Q4 Earnings

MannKind (MNKD) Stock Down in After-Hours Trading on Q4 Earnings

MannKind (MNKD) stock is declining in after-hours trading on Monday after reporting its 2015 fourth quarter financial results.

MannKind Corporation Reports 2015 Fourth Quarter And Full Year Financial Results

MannKind Corporation Reports 2015 Fourth Quarter And Full Year Financial Results

Conference Call to Begin Today at 5:00 PM ET

What's Ahead for the Week: Can FedEx Deliver Strong Results?

What's Ahead for the Week: Can FedEx Deliver Strong Results?

In addition to FedEx, Oracle, Adobe Systems and Tiffany will report quarterly earnings this coming week.

What's Ahead for the Week: Can FedEx Deliver a Strong Quarter?

What's Ahead for the Week: Can FedEx Deliver a Strong Quarter?

In 'What's Ahead on Wall Street' for the week of March 14, we have a mix of both earnings and economic data.

MannKind (MNKD) Stock Spiked Ahead of Q4 Earnings

MannKind (MNKD) Stock Spiked Ahead of Q4 Earnings

MannKind (MNKD) shares closed Thursday's trading session up ahead of the company's 2015 fourth quarter financial results.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of MannKind Corp. Of Class Action Lawsuit And A Lead Plaintiff Deadline Of March 15, 2016

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of MannKind Corp. Of Class Action Lawsuit And A Lead Plaintiff Deadline Of March 15, 2016

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of MannKind Corporation ("MannKind" or the "Company") (Nasdaq:MNKD)...

Rockwell Medical's 'Exceptional Year' of Nonexistent Dialysis Drug Sales

Rockwell Medical's 'Exceptional Year' of Nonexistent Dialysis Drug Sales

On Monday night, Rockwell admitted to investors it managed to 'sell' a kidney dialysis product for the last four months of 2015 without actually selling any of the product.

INVESTOR ALERT: The Law Offices Of Vincent Wong Notify Investors Of Class Action Involving MannKind Corp. And A Lead Plaintiff Deadline Of March 15, 2016

INVESTOR ALERT: The Law Offices Of Vincent Wong Notify Investors Of Class Action Involving MannKind Corp. And A Lead Plaintiff Deadline Of March 15, 2016

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Central District of California on behalf of investors who purchased MannKind Corp.